Pediatric Infectious Disease

Register      Login

VOLUME 1 , ISSUE 1 ( January-March, 2019 ) > List of Articles


Central Nervous System Tuberculosis in Children

PAM Kunju, Joe James

Keywords : Antituberculous treatment, Tuberculous meningitis, Tuberculous meningitis diagnosis, Tuberculous meningitis treatment

Citation Information : Kunju P, James J. Central Nervous System Tuberculosis in Children. Pediatr Inf Dis 2019; 1 (1):23-29.

DOI: 10.5005/jp-journals-10081-1106

License: CC BY-NC 4.0

Published Online: 01-10-2019

Copyright Statement:  Copyright © 2019; The Author(s).


The emergence of multidrug-resistant and extensively drug-resistant tuberculosis (TB) and the advent of acquired immunodeficiency syndrome (AIDS) have complicated the diagnosis and treatment of central nervous system tuberculosis in children. Manifestations of central nervous system (CNS) TB varies from meningeal involvement to compressive myelopathy from vertebral TB. Rapid recognition of tuberculous meningitis (TBM) is essential as delays in initiating treatment are associated with poor outcome. Delayed diagnosis and treatment of TBM heralds’ poor neurological outcomes. The laboratory diagnosis of TBM is hampered by the low yield from CSF and the slow growth of M. tuberculosis. The current schedule of treatment of TBM has undergone a considerable change and is now aimed at the elimination of TB by 2030. In this review, we examine the recent advances in the understanding of TBM, its diagnosis, and the treatment.

PDF Share
  1. Global tuberculosis report 2018. Geneva: World Health Organization;
  2. Licence: CC BY-NC-SA 3.0 IGO.
  3. YK Amdekar Consensus Statement on Childhood Tuberculosis; Working Group on Tuberculosis, Indian Academy of Pediatrics (IAP) Indian Pediatr 2010;47: 41-55
  4. Rom W. Garay S. Tuberculosis. Philadelphia, PA: Lippincott Williams & Wilkins; 2004.
  5. Donald PR, Schaaf HS, Schoeman JF. Tuberculous meningitis and miliary tuberculosis: the Rich focus revisited. J Infect. 2005;50(3):193- 195.
  6. Rich AR, McCordock HA. The pathogenesis of tuberculous meningitis. Bull Johns Hopkins Hosp. 1933;52:5-37.
  7. James J. Central nervous system tuberculosis – The gray area in tuberculosis treatment. J Neurosci Rural Pract. 2019;10(1):6. doi:10.4103/jnrp.jnrp_229_18.
  8. Sütlaş PN, Unal A, Forta H, Senol S, Kirbaş D. Tuberculous meningitis in adults: review of 61 cases. Infection. 2003;31(6):387-391. doi:10.1007/s15010-003-3179-1.
  9. Cherian A, Thomas SV. Central nervous system tuberculosis. Afr Health Sci. 2011;11(1):116-127.
  10. Kennedy DH, Fallon RJ. Tuberculous meningitis. JAMA. 1979;241(3):264- 268.
  11. Zunt J R, Tuberculosis of the Central Nervous System. CONTINUUM (MINNEAP MINN) 2018;24(5, NEUROINFECTIOUS DISEASE):1422-1438
  12. Sharma P, Garg RK, Verma R, et al. Incidence, predictors and prognostic value of cranial nerve involvement in patients with tuberculous meningitis: a retrospective evaluation. Eur J Intern Med. 2011;22(3):289-295.
  13. Garg RK. Tuberculosis of the central nervous system. Postgrad Med J. 1999;75(881):133 LP-140.
  14. Mahadevan A. The enigma of tuberculous vasculopathy - Is it time to review our dogmas?. Neurol India [serial online] 2016 [cited 2019 Jan 15];64:864-867. Available from:
  15. Dastur DK, Lalitha V, Udani PM, et al. The brain and meninges in tuberculous meningitis. Gross pathology in 100 cases and pathogenesis. Neurology 1970; 18:86-100
  16. Lammie GA, Hewlett RH, Schoeman JF, et al. Tuberculous cerebrovascular disease: A review. J Infect 2009;59:156-166.
  17. Lincoln, E. Tuberculous meningitis in children; with special reference to serous meningitis; tuberculous meningitis. Amer Rev Tuberc 1947; 56:75.
  18. Luthra G, Parihar A, Nath K, et al. Comparative Evaluation of Fungal, Tubercular, and Pyogenic Brain Abscesses with Conventional and Diffusion MR Imaging and Proton MR Spectroscopy. Am J Neuroradiol 2007;28(7):1332-1338.
  19. Kim HJ1, Shim KW, Lee MK, et al. Tuberculous encephalopathy without meningitis: pathology and brain MRI findings. Eur Neurol. 2011;65(3):156-159.
  20. Dastur DK, Manghani DK, Udani PM. Pathology and pathogenetic mechanisms in neurotuberculosis. Radiol Clin Nor th Am 1995;33(4):733-752.
  21. Bagga A, Kalra V, Ghai OP. Intracranial tuberculoma, Clinical Pediatrics 1988;27(10):487-490.
  22. Cheng VC, Yam WC, Woo PC, et al. Risk factors for development of paradoxical response during antituberculosis therapy in HIV-negative patients. Eur J Clin Microbiol Infect Dis. 2003;22:597-602.
  23. Kar thik SN, Bhanu K, Velayutham S, et al. Hyper trophic pachymeningitis. Ann Indian Acad Neurol 2011;14(3):203-204.
  24. Prabhakar S, Bhatia R, Lal V, et al. Hypertrophic pachymeningitis: varied manifestations of a single disease entity. Neurol India. 2002;50(1):45-52.
  25. Yamashita K, Suzuki Y, Yoshizumi H, et al. Tuberculous hypertrophic pachymeningitis involving the posterior fossa and high cervical region--case report. Neurol Med Chir (Tokyo) 1994;34(2):100-103.
  26. Tariq R, Ahmed R. Tuberculous hypertrophic pachymeningitis presenting as visual blurring and headaches. J Pak Med Assoc. 2012;62(9):966-968.
  27. Dunn RN, Ben Husien M. Spinal tuberculosis. Bone Joint J 2018 Apr
  28. 100-B (4):425-431.
  29. Turgut M. Spinal tuberculosis (Pott's disease): its clinical presentation, surgical management, and outcome. A survey study on 694 patients. Neurosurg Rev 2001;24(1):8-13.
  30. Fuentes Ferrer M, Gutierrez Torres L, Ayala Ramirez O, et al. Tuberculosis of the spine. A systematic review of case series. Int Orthop. 2012;36(2):221-231.
  31. Thakur R, Goyl R, Sarma S. Laboratory Diagnosis of Tuberculous Meningitis. Is There a Scope for Further Improvement?J Lab Physicians 2010;2(1):21-24.
  32. Hernandez-Albujar S, Arribas JR, Royo A, et al. Tuberculous radiculomyelitis complicating tuberculous meningitis: case report and review. Clin Infect Dis 2000;30(6):915-921.
  33. Link-Gelles R, Moultrie H, Sawry S, et al. Tuberculosis Immune Reconstitution Inflammatory Syndrome in children initiating Antiretroviral Therapy for HIV infection: A systematic literature review; Pediatr Infect Dis J. 2014;33(5):499-503
  34. Chen P, Shi M, Feng GD, et al. A highly efficient Ziehl-Neelsen stain: identifying de novo intracellular Mycobacterium tuberculosis and improving detection of extracellular M. tuberculosis in cerebrospinal fluid, J Clin Microbiol 2012;50:1166-1170.
  35. Caviedes L, Lee TS, Gilman RH, et al. Rapid, efficient detection and drug susceptibility testing of Mycobacterium tuberculosis in sputum by microscopic observation of broth cultures. The Tuberculosis Working Group in Peru, J Clin Microbiol 2000;38:pg. 1203-1208.
  36. Sertel Şelale D, Uzun M. The value of microscopic-observation drug susceptibility assay in the diagnosis of tuberculosis and detection of multidrug resistance. Apmis 2018;126(1):38-44.
  37. Ekermans P, Duse A, George J. The dubious value of cerebrospinal fluid adenosine deaminase measurement for the diagnosis of tuberculous meningitis. BMC Infect Dis 2017;17:104.
  38. Xu H-B, Jiang R-H, Li L, Sha W, et al. Diagnostic value of adenosine deaminase in cerebrospinal fluid for tuberculous meningitis: a metaanalysis. Int J Tuberc Lung Dis 2010;14(11):1382-1387.
  39. Kent SJ, Crowe SM, Yung A, et al. Tuberculous Meningitis: A 30-Year Review. Clin Infect Dis. 1993;17(6):987-994.
  40. Pai M, Flores LL, Pai N, et al. Diagnostic accuracy of nucleic acid amplification tests for tuberculous meningitis: a systematic review and meta-analysis. Lancet Infect Dis 2003;3(10):633-643.
  41. Thwaites GE, Caws M, Chau TTH, et al. Comparison of conventional bacteriology with nucleic acid amplif ication (amplif ied mycobacterium direct test) for diagnosis of tuberculous meningitis before and after inception of antituberculosis chemotherapy. J Clin Microbiol 2004;42(3):996-1002.
  42. WHO meeting report of a technical expert consultation: noninferiority analysis of Xpert MTF/RIF Ultra compared to Xpert MTB/RIF. Geneva: World Health Organization; 2017 (WHO/HTM/TB/2017.04). Licence: CC BY-NCSA 3.0 IGO.
  43. Index TB Guidelines. Guidelines on extra-pulmonary tuberculosis for India. World Health Organization; 2016.
  44. Sharma SK, Ryan H, Khaparde S, et al. Index-TB guidelines: guidelines on extrapulmonary tuberculosis for India. Indian J Med Res 2017;145(4):448-463.
  45. Kumar GS, Venugopal AK, Mahadevan A, Renuse S, Harsha HC, et al. Quantitative proteomics for identifying biomarkers for tuberculous meningitis. Clin Proteomics 2012;9(1):12.
  46. Paris L, Magni R, Zaidi F, et al. Urine lipoarabinomannan glycan in HIV-negative patients with pulmonary tuberculosis correlates with disease severity. Sci Transl Med 2017;9(420).
  47. Kumar R, Singh SN, Kohli N. A diagnostic rule for tuberculous meningitis. Arch Dis Child 1999;81:221-224.
  48. Marais S, Thwaites G, Schoeman JF, et al. Tuberculous meningitis: a uniform case definition for use in clinical research. Lancet Infect Dis 2010;10(11):803-812.
  49. Thomas B, Thamburaj K, Kesavadas C. ‘Eiffel-by-Night’: A New MR Sign Demonstrating Reactivation in Idiopathic Hypertrophic Pachymeningitis. Neuroradiol J 2007;20(2):194-195.
  50. “WHO treatment guidelines for drug resistant tuberculosis (2018 update)”, WHO, Geneva, 2018
  51. Thwaites GE, Nguyen DB, Nguyen HD, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults, N Engl J Med 2004;351:1741-1751.
  52. Schoeman JF, Janse van Rensburg A, Laubscher JA, et al. The role of aspirin in childhood tuberculous meningitis, J Child Neurol 2011;26:956-962.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.